Angiotensin II (3-8), human TFA



Cat. No.:	HY-P1515A
Molecular Formula:	$C_{42}H_{55}F_3N_8O_{10}$
Molecular Weight:	888.93
Target:	Angiotensin Receptor
Pathway:	GPCR/G Protein
Storage:	Sealed storage, away from moisture Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

SOLVENT & SOLUBILITY

In Vitro

H_2O : 50 mg/mL (56.25 mM; Need ultrasonic)

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	1.1249 mL	5.6247 mL	11.2495 mL
5 mM	0.2250 mL	1.1249 mL	2.2499 mL
10 mM	0.1125 mL	0.5625 mL	1.1249 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Angiotensin II (3-8), human (TFA) is a less effective agonist at the angiotensin AT_1 receptor.

IC_{50} & Target

Angiotensin AT_1 receptor[1].

In Vivo

Human Angiotensin II (3-8) causes endothelium-dependent renal cortical vasodilatation, in anaesthetized rats. At doses up to 125 pmol/kg, human Angiotensin II (3-8) is without any cardiovascular effects, but with doses of 1.25 and 12.5 nmol/kg there are dose-dependent increases in mean arterial blood pressure and reductions in renal and mesenteric flows and vascular conductances[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Animal Administration [1]

Rats[1]

Male Long Evans rats (350-450 g) (n=7) are given increasing bolus doses of AII (1.25, 12.5 and 125 pmol/kg) or human

Angiotensin II (3-8) (0.125, 1.25 and 12.5 nmol/kg) in random order, in the morning or afternoon of the same experimental day. Injections are separated by at least 20 min to allow variables to return to baseline[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Theranostics. 2021 Jul 25;11(18):8624-8639.
- Eur J Pharmacol. 2019 Mar 13;853:93-102.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Gardiner SM, et al. Regional haemodynamic effects of angiotensin II (3-8) in conscious rats. Br J Pharmacol. 1993 Sep;110(1):159-62.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA